Before joining I-Mab, Dr. Dennis was Vice President of Lung Cancer Strategy and the Global Project Head for a novel, first-in-class ADC at Sanofi (NASDAQ: SNY). Prior to Sanofi, Dr. Dennis was Vice President of Lung Cancer Strategy and Global Clinical Lead at AstraZeneca (NASDAQ: AZN). In these roles, Dr. Dennis served as the disease strategy head for lung cancer and led the cross-functional development of key assets, including IMFINZI®. Prior to his pharmaceutical career, Dr. Dennis was a widely published professor of Oncology, Medicine, and Pharmacology at Johns Hopkins University. Dr. Dennis received his MS, MD, and PhD degrees from the New York University School of Medicine as part of the Medical Scientist Training Program. Dr. Dennis completed his residency in Internal Medicine and fellowship in Medical Oncology at Johns Hopkins. Dr. Dennis also spent 14 years as a translational researcher at the US National Cancer Institute, achieving tenure as a Senior Investigator. He is an elected member of the American Society for Clinical Investigation and has won several awards, including an NIH Merit Award.
Skelton先生作为一位具有深厚资本市场交易背景的财务策略专家，曾参与及主导的累计交易价值超过200亿美元。在加入天境之前曾在Truist Securities任职生物制药领域高级副总裁。Skelton先生在金融领域拥有包括在医疗保健投资银行和制药领域逾十年经验的丰富背景，他在Cantor Fitzgerald以及Amneal Pharmaceuticals就职期间曾担任金融顾问等角色，参与并主导了多个关键战略项目。
徐聪博士在2018年天境生物美国分公司成立之初加入公司。她带领团队建立了马里兰州研发中心。徐聪博士负责公司全球管线在美国的医学/临床研究、临床运营、注册事务、临床标记物和项目管理。她的团队与中国团队紧密合作，共同推进全球临床研究策略和实施。
在加入天境生物之前，徐聪博士是大冢制药美国分公司临床药理副主管，负责过多个治疗领域包括肿瘤及血液病的临床1/2期试验。徐聪博士获得了美国印第安纳大学医学院临床药理学博士学位和中山大学医学院学士学位。